ST2 is an IL-1 receptor family member with transmembrane (ST2L) and soluble (sST2) isoforms. sST2 is a mechanically induced cardiomyocyte protein, and serum sST2 levels predict outcome in patients with acute myocardial infarction or chronic heart failure. Recently, IL-33 was identified as a functional ligand of ST2L, allowing exploration of the role of ST2 in myocardium. We found that IL-33 was a biomechanically induced protein predominantly synthesized by cardiac fibroblasts. IL-33 markedly antagonized angiotensin II– and phenylephrine-induced cardiomyocyte hypertrophy. Although IL-33 activated NF-κB, it inhibited angiotensin II– and phenylephrine-induced phosphorylation of inhibitor of NF-κBα (IκBα) and NF-κB nuclear binding activity. sST2 blocked antihypertrophic effects of IL-33, indicating that sST2 functions in myocardium as a soluble decoy receptor. Following pressure overload by transverse aortic constriction (TAC), ST2–/– mice had more left ventricular hypertrophy, more chamber dilation, reduced fractional shortening, more fibrosis, and impaired survival compared with WT littermates. Furthermore, recombinant IL-33 treatment reduced hypertrophy and fibrosis and improved survival after TAC in WT mice, but not in ST2–/– littermates. Thus, IL-33/ST2 signaling is a mechanically activated, cardioprotective fibroblast-cardiomyocyte paracrine system, which we believe to be novel. IL-33 may have therapeutic potential for beneficially regulating the myocardial response to overload.
Shoji Sanada, Daihiko Hakuno, Luke J. Higgins, Eric R. Schreiter, Andrew N.J. McKenzie, Richard T. Lee
Title and authors | Publication | Year |
---|---|---|
Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology
SJ Forrester, GW Booz, CD Sigmund, TM Coffman, T Kawai, V Rizzo, R Scalia, S Eguchi |
Physiological reviews | 2018 |
Triggering Endogenous Cardiac Repair and Regeneration via Extracellular Vesicle-Mediated Communication
S Bollini, AM Smits, C Balbi, E Lazzarini, P Ameri |
Frontiers in physiology | 2018 |
The Janus face of HMGB1 in heart disease: a necessary update
A Raucci, SD Maggio, F Scavello, A DAmbrosio, ME Bianchi, MC Capogrossi |
Cellular and Molecular Life Sciences | 2018 |
Hepatokine α1-Microglobulin Signaling Exacerbates Inflammation and Disturbs Fibrotic Repair in Mouse Myocardial Infarction
D Hakuno, M Kimura, S Ito, J Satoh, Y Nakashima, T Horie, Y Kuwabara, M Nishiga, Y Ide, O Baba, H Nishi, T Nakao, T Nishino, F Nakazeki, S Koyama, R Hanada, RR Randolph, J Endo, T Kimura, K Ono |
Scientific Reports | 2018 |
Mechanisms of Cardiac Repair and Regeneration
KM Broughton, BJ Wang, F Firouzi, F Khalafalla, S Dimmeler, F Fernandez-Aviles, MA Sussman |
Circulation research | 2018 |
Interleukin-33 and ST2 Signaling in Tumor Microenvironment
J Hong, S Kim, PC Lin |
Journal of Interferon & Cytokine Research | 2018 |
Critical Roles of IL-33/ST2 Pathway in Neurological Disorders
MF Isnadi, VK Chin, RA Majid, TY Lee, MA Abdullah, RB Omenesa, ZO Ibraheem, R Basir |
Mediators of Inflammation | 2018 |
The Effect of Left Ventricular Assist Device Therapy on Cardiac Biomarkers: Implications for the Identification of Myocardial Recovery
L Holzhauser, G Kim, G Sayer, N Uriel |
Current Heart Failure Reports | 2018 |
Interleukin-33 Receptor (ST2) Deficiency Improves the Outcome of Staphylococcus aureus-Induced Septic Arthritis
L Staurengo-Ferrari, SC Trevelin, V Fattori, DC Nascimento, KA de Lima, JS Pelayo, F Figueiredo, R Casagrande, SY Fukada, MM Teixeira, TM Cunha, FY Liew, RD Oliveira, P Louzada-Junior, FQ Cunha, JC Alves-Filho, WA Verri |
Frontiers in immunology | 2018 |
Correlations of GDF-15 with sST2, MMPs, and worsening functional capacity in idiopathic dilated cardiomyopathy: Can we gain new insights into the pathophysiology?
N Nair, E Gongora |
Journal of Circulating Biomarkers | 2018 |
Current and future circulating biomarkers for cardiac amyloidosis
M Luciani, L Troncone, FD Monte |
Acta Pharmacologica Sinica | 2018 |
The Association Between Novel Biomarkers and 1-Year Readmission or Mortality After Cardiac Surgery
JP Jacobs, SS Alam, SL Owens, DM Parker, M Rezaee, DS Likosky, DM Shahian, ML Jacobs, H Thiessen-Philbrook, MW von Ballmoos, K Lobdell, T MacKenzie, AD Everett, CR Parikh, JR Brown |
The Annals of Thoracic Surgery | 2018 |
The Role of IL-33/ST2 Pathway in Tumorigenesis
K Larsen, M Minaya, V Vaish, M Peña |
International journal of molecular sciences | 2018 |
ST2: Current status
A Dattagupta, S Immaneni |
Indian Heart Journal | 2018 |
Predictive value of soluble ST2 in adolescent and adult patients with complex congenital heart disease
M Laqqan, C Schwaighofer, S Graeber, T Raedle-Hurst, C Passino |
PloS one | 2018 |
GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2
S Stojkovic, A Kaider, L Koller, M Brekalo, J Wojta, A Diedrich, S Demyanets, T Pezawas |
Journal of Cellular and Molecular Medicine | 2018 |
The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers
M Nishimura, A Brann, KW Chang, AS Maisel |
Current Heart Failure Reports | 2018 |
IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE2
Y Li, J Shi, S Qi, J Zhang, D Peng, Z Chen, G Wang, Z Wang, L Wang |
Journal of Experimental & Clinical Cancer Research | 2018 |
Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV
C deFilippi, R Christenson, J Joyce, EA Park, A Wu, KV Fitch, SE Looby, MT Lu, U Hoffmann, SK Grinspoon, J Lo |
Journal of acquired immune deficiency syndromes (1999) | 2018 |
Down-regulation of microRNA-203-3p initiates type 2 pathology during schistosome infection via elevation of interleukin-33
X He, J Xie, Y Wang, X Fan, Q Su, Y Sun, N Lei, D Zhang, G Gao, W Pan, P Loke |
PLoS pathogens | 2018 |
Elevated Levels of Soluble ST2 were Associated with Rheumatoid Arthritis Disease Activity and Ameliorated Inflammation in Synovial Fibroblasts
LJ Shi, C Liu, JH Li, XY Zhu, YN Li, JT Li |
Chinese Medical Journal | 2018 |
Cardioprotective cytokine interleukin-33 is up-regulated by statins in human cardiac tissue
R Pentz, C Kaun, B Thaler, S Stojkovic, M Lenz, KA Krychtiuk, A Zuckermann, K Huber, J Wojta, PJ Hohensinner, S Demyanets |
Journal of Cellular and Molecular Medicine | 2018 |
sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction
M Plawecki, M Morena, N Kuster, L Chenine, H Leray-Moragues, B Jover, P Fesler, M Lotierzo, AM Dupuy, K Klouche, JP Cristol |
Mediators of Inflammation | 2018 |
IL-33/ST2 Axis in Organ Fibrosis
OS Kotsiou, KI Gourgoulianis, SG Zarogiannis |
Frontiers in immunology | 2018 |
Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
M Kieler, M Unseld, J Wojta, A Kaider, D Bianconi, S Demyanets, GW Prager |
Medical Oncology | 2018 |
Interleukin-33 (IL-33) Increases Hyperoxia-Induced Bronchopulmonary Dysplasia in Newborn Mice by Regulation of Inflammatory Mediators
X Tang |
Medical science monitor : international medical journal of experimental and clinical research | 2018 |
Exercise-induced Changes in Soluble ST2 Concentrations in Marathon Runners:
VI Aengevaeren, RR Kimmenade, MT Hopman, NV Royen, JV Snider, JL Januzzi, KP George, TM Eijsvogels |
Medicine and Science in Sports and Exercise | 2018 |
Cardiac Biomarkers: What Is and What Can Be
R Jacob, M Khan |
2018 |